← Back to Search

Reproxalap Ophthalmic Solution (0.25%) for Allergic Eye

Phase 3

Waitlist Available

Research Sponsored by Aldeyra Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up during eec allergen exposure.

Awards & highlights

Study Summary

This trial is testing a new eye drop called reproxalap compared to a placebo drop. The study will involve people with seasonal allergies and will test how well the new drop works in relieving symptoms.

Eligible Conditions

Allergic Eye

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ during eec allergen exposure.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~during eec allergen exposure.

This trial's timeline: 3 weeks for screening, Varies for treatment, and during eec allergen exposure. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Ocular itching evaluated by the Subject.

Secondary outcome measures

Conjunctival redness evaluated by the Subject.

Side effects data

From 2021 Phase 2 trial • 158 Patients • NCT04971031

General disorders and administration site conditions

100%

80%

60%

40%

20%

Study treatment Arm

Vehicle

Reproxalap (0.25%)

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Reproxalap Ophthalmic Solution (0.25%)Experimental Treatment1 Intervention

Group II: Vehicle Ophthalmic SolutionPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Reproxalap Ophthalmic Solution (0.25%)

2022

Completed Phase 3

~2690

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor

29 Previous Clinical Trials

3,902 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Reproxalap Ophthalmic Solution (0.25%) received federal approval?

"We believe that Reproxalap Ophthalmic Solution (0.25%) is safe based on its Phase 3 status. This means that, in addition to supporting efficacy, there is also multiple rounds of data supporting safety."

Answered by AI

Are patient volunteers currently being accepted for this research?

"Yes, this study is currently looking for volunteers. The listing for this clinical trial was first posted on January 21st, 2022 and was updated on May 5th, 2022."

Answered by AI

What is the maximum number of participants for this research project?

"Yes, the trial is recruiting patients. According to the listing on clinicaltrials.gov, the study was first posted on 1/21/2022 and was edited on 5/5/2022. They are currently searching for 58 participants at 1 site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

2022. "The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05234554.